Search results
Author(s):
Vineet Agrawal
,
Kelly A Costopoulos
,
Mohammed Chowdhary
,
et al
Added:
2 years ago
Author(s):
James L Januzzi
,
Harriette Van Spall
Added:
9 months ago
ESC-HFA 2023 - Late-Breaker host, Dr Harriette Van Spall (McMaster University, CA) is joined by Dr James Januzzi (Massachusetts General Hospital, US) to discuss the findings of the TRACER-HF trial.
Trientine-HCL is an oral chelation agent. Preclinical trials suggest that this promotes a reverse cardiac remodelling effect in HFrEF patients. 200 patients with New York Heart Association Class II or…
View more
Author(s):
Nicolas Meneveau
,
Andrew SP Sharp
,
Adriaan Kraaijeveld
Added:
5 years ago
Acoustic pulse thrombolysis treatment for pulmonary embolism patients: rationale, experience and data
Satellite symposium at ESC Congress 2018 sponsored by EKOS Corporation
Part 1: Prof Nicolas Meneveau - (Besancon, FR)
Part 2: Prof Andrew Sharp - (Exeter, UK)
Part 3: Prof Adriaan Kraaijeveld - (Utrecht, NL)
View more
Author(s):
Thomas A Zelniker
,
Eugene Braunwald
Added:
3 years ago
With progressive ageing and the growing incidence of obesity in the population, the prevalence of type 2 diabetes (T2D) has been rising rapidly and has become a major cause of death and disability worldwide.1 It is well established that atherosclerotic cardiovascular disease (ASCVD) and renal failure are responsible for a large majority of deaths in patients with T2D.2-4 Over the past decade, the…
View more
Author(s):
João Morais
Added:
7 years ago
Biography
João Morais is Chief of the Cardiology Division and Chairman of the Clinical Research Centre of Leiria Hospital, Portugal. He is Past-Chair of the ESC Working Group on Thrombosis, member of the scientific committee of ESC congress (2014-2018) and also of ACCA (2014-2016) and has been a member of several task forces throughout his career [Stable Angina (2006); Antiplatelets (2011 and…
View more
Author(s):
Martin R Cowie
,
Michel Komajda
Added:
3 years ago
Advances in diagnosis and treatment have improved the outlook for the estimated 26 million patients with heart failure (HF) worldwide,1 but there remains a continuing need for further reduction in mortality and hospitalisation and the associated social and financial consequences of the disease. In a European study of outcomes after HF hospitalisation, 17 % of patients died within 12 months and 44…
View more
HFA 2017 : Multi-center RCT of the Efficacy of LV Augmentation with Algisyl in the Treatment of HF
Author(s):
Andrew JS Coats
Added:
6 years ago
Video
Author(s):
Josip Katic
,
Josip A Borovac
Added:
11 months ago
Author(s):
John Pepper
Added:
3 years ago
The most common cause of heart failure with reduced ejection fraction (HFrEF) in the industrialised world is coronary heart disease.1 Patients with an ischaemic aetiology of left ventricular systolic dysfunction have significantly higher mortality rates than those with non-ischaemic aetiologies.2 This more aggressive course represents the convergence of ischaemic myocardial fibrosis and…
View more
Author(s):
Izabella Uchmanowicz
,
Anna Chudiak
,
Beata Jankowska-Polańska
,
et al
Added:
3 years ago
Hypertension is considered the most common disorder in the general population. It is both a health and a financial problem worldwide. The Writing Group of the American Society of Hypertension defines hypertension as a cardiovascular syndrome resulting from a number of interconnected factors.1 Therefore, a comprehensive evaluation is required, involving both the cardiovascular system and other…
View more